scPharmaceuticals Announced Topline Results From The Pharmacokinetic Study Of SCP-111, An Investigational, Low Volume, Ph-neutral Formulation Of Furosemide Administered Via An Autoinjector As An Alternative To The Current On-body Infusor Used With Furoscix
Portfolio Pulse from Benzinga Newsdesk
scPharmaceuticals announced positive topline results from the pharmacokinetic study of SCP-111, a low volume, pH-neutral formulation of furosemide administered via an autoinjector. SCP-111 demonstrated high bioavailability and similar efficacy to IV furosemide with minimal pain and manageable adverse events.
August 12, 2024 | 10:04 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
scPharmaceuticals' SCP-111 showed high bioavailability and similar efficacy to IV furosemide with minimal pain and manageable adverse events in a recent study.
The positive topline results for SCP-111, including high bioavailability and minimal pain, are likely to boost investor confidence in scPharmaceuticals. This could lead to a short-term increase in SCPH stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100